Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | PTPRC | P08575 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009937 | 1.00 | PTGS2 (0.66) | PTGS2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2692579 | 0.93 | CA12 (0.59) | PTGS2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL29629010 | 0.89 | PTGS2 (0.58) | PTGS2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL17876319 | 0.85 | PTPRC (0.53) | PTGS2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL22162812 | 0.84 | CA12 (0.58) | PTGS2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL25440225 | 0.83 | RAB9A (0.65) | PTGS2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30662425 | 0.83 | PTGS2 (0.57) | PTGS2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL9903729 | 0.82 | LMNA (0.59) | PTGS2SMN1; SMN2MAPTKDM4ELMNA | |
| Biphenyl SCHEMBL27625903 | 0.82 | ADORA1 (0.55) | PTGS2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL17876110 | 0.82 | PTPRC (0.50) | PTGS2NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104628910-B | Catalyst for producing polypropylene with high isotacticity and preparation method thereof | 中国石油天然气股份有限公司 | 2017-02-08 | — | — | CN | claimed |
| CN-104628910-A | Catalyst for producing polypropylene with high isotacticity and preparation method thereof | PETROCHINA CO LTD | 2015-05-20 | — | — | CN | claimed |
| CN-110072844-B | Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni | 英特维特国际股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2023-01-05 | — | — | US | disclosed |
| CN-110300578-B | Compounds for the treatment of respiratory diseases in cattle or pigs | 英特维特国际股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | INTERVET INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20200085779-A1 | Compounds for the Treatment of Bovine or Swine Respiratory Disease | INTERVET INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-3122707-B1 | METHOD FOR COUPLING A FIRST AROMATIC COMPOUND TO A SECOND AROMATIC COMPOUND | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2004113335-A2 | PYRIDINO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004111058-A1 | HETERORYL-FUSED PYRIMIDINYL COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | PTGS2 3798/4885NPC1 4125/4885RAB9A 1662/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | PTGS2 3583/4885NPC1 4460/4885RAB9A 1810/4885 |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | PTGS2 1947/4885NPC1 1651/4885RAB9A 833/4885 |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | SORD, HEXD, SDHA | PTGS2 889/4885NPC1 2819/4885RAB9A 2100/4885 |
| US-11202775-B2 | Methods for treatment of cancer | TP53, TOP2B, BRCA1 | PTGS2 2087/4885NPC1 445/4885RAB9A 3686/4885 |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | PI4KB, PI4KA, PDPK1 | PTGS2 1649/4885NPC1 666/4885RAB9A 778/4885 |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | PTGS2 2087/4885NPC1 445/4885RAB9A 3686/4885 |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | PTGS2 2705/4885NPC1 1109/4885RAB9A 881/4885 |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, BRD1 | PTGS2 1439/4885NPC1 276/4885RAB9A 2082/4885 |
| US-20200085779-A1 | Compounds for the Treatment of Bovine or Swine Respiratory Disease | PIGS, BTD, PPARD | PTGS2 1409/4885NPC1 394/4885RAB9A 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.